Physician profile
Ibrahim Ibrahim
NPI 1699975540
$1,143.17
in general payments reported to CMS, 2019-2025
13 companies · $92.67 in 2025
The $92.67 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.02 · 2021: $110 · 2022: $113 · 2023: $769 · 2025: $92.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Food and Beverage: $339 · Education: $22.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Food and Beverage | $339.16 |
| Education | $22.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $500.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $228.72 | 2021-2023 | |
| Genzyme Corporation | $99.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.12 | 2023 | |
| Pfizer INC. | $48.45 | 2023 | |
| Genetix Biotherapeutics INC | $44.63 | 2025 | Lyfgenia |
| E.R. Squibb & Sons, L.L.C. | $38.62 | 2019-2025 | Opdualag |
| Genentech USA, INC. | $38.00 | 2019 | |
| Chiesi USA, INC. | $29.44 | 2025 | Cleviprex |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Spark Therapeutics, INC. | $19.25 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.47 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.